scholarly journals Role of COUP-TFI during retinoic acid-induced differentiation of P19 cells to endodermal cells

2012 ◽  
Vol 228 (4) ◽  
pp. 791-800 ◽  
Author(s):  
Brandy S. Pickens ◽  
Bryan W. Teets ◽  
Kenneth J. Soprano ◽  
Dianne Robert Soprano
FEBS Letters ◽  
2010 ◽  
Vol 584 (22) ◽  
pp. 4661-4664 ◽  
Author(s):  
Maryam Shahhoseini ◽  
Raha Favaedi ◽  
Hossein Baharvand ◽  
Vikram Sharma ◽  
Hendrik G Stunnenberg

2020 ◽  
Vol 21 (19) ◽  
pp. 7192
Author(s):  
Paweł Leszczyński ◽  
Magdalena Śmiech ◽  
Aamir Salam Teeli ◽  
Effi Haque ◽  
Robert Viger ◽  
...  

PRDM (PRDI-BF1 (positive regulatory domain I-binding factor 1) and RIZ1 (retinoblastoma protein-interacting zinc finger gene 1) homologous domain-containing) transcription factors are a group of proteins that have a significant impact on organ development. In our study, we assessed the role of Prdm3 in neurogenesis and the mechanisms regulating its expression. We found that Prdm3 mRNA expression was induced during neurogenesis and that Prdm3 gene knockout caused premature neuronal differentiation of the P19 cells and enhanced the growth of non-neuronal cells. Interestingly, we found that Gata6 expression was also significantly upregulated during neurogenesis. We further studied the regulatory mechanism of Prdm3 expression. To determine the role of GATA6 in the regulation of Prdm3 mRNA expression, we used a luciferase-based reporter assay and found that Gata6 overexpression significantly increased the activity of the Prdm3 promoter. Finally, the combination of retinoic acid receptors α and β, along with Gata6 overexpression, further increased the activity of the luciferase reporter. Taken together, our results suggest that in the P19 cells, PRDM3 contributed to neurogenesis and its expression was stimulated by the synergism between GATA6 and the retinoic acid signaling pathway.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1199-1199
Author(s):  
Patricia Vanessa Sanchez ◽  
Reid P Bissonnette ◽  
Donald E Tsai ◽  
Martin Carroll

Abstract Despite advances in understanding the molecular pathogenesis of acute myeloid leukemia (AML), therapy for relapsed disease remains inadequate with high mortalities. Clinicians at the University of Pennsylvania have demonstrated that the FDA approved retinoid X receptor (RXR) agonist bexarotene (Targretin™) stimulates leukemic cell differentiation in a subset patents with relapsed AML leading to clinical responses. This underscores the importance of identifying the mechanism by which bexarotene induces differentiation in AML in order to enhance the efficacy of this therapeutic approach. To understand the role of bexarotene and RXR receptors in leukemic cell differentiation, we initially utilized a pharmacogenetic approach to study the effects of bexarotene on AML cell lines using combinations of bexarotene with other differentiation induction agents. These studies demonstrate that bexarotene induces myeloid differentiation in MOLM14, HL60, THP-1, and NB4 cell lines but not in the myeloblastic cell line KG1a. Combination treatment of AML cell lines with bexarotene in combination with all trans retinoic acid (ATRA) enhanced differentiation suggesting that the mechanism of action for bexarotene is through RARα (retinoic acid receptor)/RXRα heterodimer stimulation. Consistent with this, differentiation induced by the drug combination was effectively blocked by the RAR antagonist, LG100815 and partially blocked by the RXR antagonist, LG101208. In contrast, bexarotene does not cooperate with valproic acid, theophylline, the PPARγ agonist rosiglitazone, or the LXR agonist T0901317. Preliminary data from quantitative RT-PCR and Affymetrix microarray analysis of bexarotene responsive AML cell lines at 3, 6, 12, and 96 hours post treatment has identified a subset of genes potentially regulated by bexarotene. CEBPε, a transcription factor known to play a critical role in granulopoiesis and PIM-1, a known oncogenic transcription factor, were among the genes that were significantly upregulated after bexarotene treatment of AML cells. Analysis of the functional role of C/EBPε in retinoid induced differentiation will be presented. Overall, this data supports the hypothesis that bexarotene, like ATRA, induces myeloid differentiation through activation of a RAR/RXR heterodimeric partner. However, other data suggests the presence of RAR independent pathways of signaling. LG100268, a pure RXR agonist induced myeloid differentiaton although not as robustly as bexarotene. Analysis of RAR and RXR mRNA expression in AML cell lines demonstrates that bexarotene does not induce expression of RARβ or p21, known targets induced by ATRA during myeloid differentiation. Chromatin immunoprecipitation assays demonstrate RXRα occupancy at RARβ and p21 promoter regions containing retinoid response elements (RARE). However, expression of these genes does not correlate with bexarotene-induced differentiation. This data suggests that although their expression has been linked to ATRA responsiveness, induction of RARβ and p21 expression is not necessary for retinoid induced myeloid differentiation. In summary, bexarotene induces myeloid differentiation through RAR dependent and independent pathways. Further analysis of the signaling events necessary for induction of myeloid differentiation by bexarotene may allow for improved selection of patients with AML who will respond to bexarotene.


2016 ◽  
Vol 100 ◽  
pp. S106-S107 ◽  
Author(s):  
Mariapaola Nitti ◽  
Sabrina Piras ◽  
Anna Lisa Furfaro ◽  
Lorenzo Brondolo ◽  
Umberto Maria Marinari ◽  
...  

1997 ◽  
Vol 44 (3) ◽  
pp. 375-381 ◽  
Author(s):  
YOSHIAKI KODAMA ◽  
YASUHIRO TAKEUCHI ◽  
TOMOKO KIKUCHI ◽  
TAKAHIDE KUROKAWA ◽  
TOSHIRO FUJITA ◽  
...  

2010 ◽  
Vol 25 (2) ◽  
pp. 71-75 ◽  
Author(s):  
Li Zhang ◽  
Li Yan ◽  
Ye Zhang ◽  
Ning-hua Wu ◽  
Yu-fei Shen
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document